Keeping Track: New Submissions In Bladder Cancer, HCV And Diabetes; Avastin Label Expands
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Keeping Track Of Novel Agents: US FDA Approves Nerlynx And Vosevi, Turns Down Evenity; Macrilen Returns
News and highlights about novel agents from our FDA Performance Tracker.
Novo Nordisk's Great Hope Semaglutide Shines In Ph II Obesity Study
Highly positive top-line weight loss results for Novo Nordisk's new GLP-1 agonist semaglutide are propelling it into Phase III trials next year for the notoriously tricky indication. The product is currently under review for type 2 diabetes.
Sun Hit As US FDA Raises Fresh Concerns Over Key Halol Plant
Indian generic giant Sun Pharma says the US FDA has flagged up new potential violations of good manufacturing practices at the company's key Halol factory, which exports a large number of products to the crucial US market and had been expected to overcome its past compliance problems.